Navigation Links
InterMune Reports First Quarter 2013 Financial Results and Business Highlights
Date:4/24/2013

not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 1, 2013 (the "Form 10-K") and other periodic reports filed with the SEC, including but not limited to the following: (i) the risks related to the uncertain, lengthy and expensive clinical development process for the company's product candidates, including having no unexpected safety, toxicology, clinical or other issues and having no unexpected clinical trial results such as unexpected new clinical data and unexpected additional analysis of existing clinical data; (ii) risks related to the regulatory process for the company's product candidates, including the possibility that the results of the new 52-week Phase 3 clinical trial (ASCEND) having an FVC endpoint may not be satisfactory to the FDA for InterMune to receive regulatory approval for pirfenidone in the United States; (iii) risks related to unexpected regulatory actions or delays or government regulation generally; (iv) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue; (v) government, industry and general public pricing pressures; (vi) risks related to our ability to successfully launch and commercialize Esbriet in Europe and Canada, including successfully establishing a commercial operation in Europe and Canada and receiving favorable governmental pricing and reimbursement approvals in the various European countries and securing coverage from private insurance plans and reimbursement from public (provincial) drug reimbursement plans in Canada; and (vii) InterMune's ability to obtain or maintain patent or other proprietary intellectual property protections.  The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other fa
'/>"/>
SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Report Unaudited Fourth Quarter EsbrietĀ® Revenue and Business Update on January 5
2. InterMune to Present at J. P. Morgan Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune To Present At JMP Securities Healthcare Conference
5. InterMune To Release Third Quarter Financial Results On November 7
6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
7. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
8. InterMune To Release First Quarter Financial Results On April 24
9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... SAN DIEGO , May 1, 2015 /PRNewswire/ ... biotechnology company engaged in the development of biosimilar ... proteins, announced today that its first quarter 2015 ... 14, 2015, before the open of market. At 8:30 ... conference call to discuss the financial results and ...
(Date:5/1/2015)... May 1, 2015 Albany Molecular Research Inc. ... S. Marth , AMRI,s President and Chief Executive Officer, ... 2015 Health Care Conference on Wednesday, May 13, 2015 ... webcast of the presentation can be accessed at AMRI,s ... The webcast will be archived for 90 days ...
(Date:4/30/2015)... April 30, 2015  Roka Bioscience, Inc. (NASDAQ: ... advanced testing solutions for the detection of foodborne pathogens, ... first quarter of 2015 on May 7, 2015 after ... Bioscience will also host a conference call at 4:30 ... its first quarter financial results. During the conference call, ...
(Date:4/30/2015)... 2015 Nitto Avecia, a leading ... increased capacity and production capability to serve biotechnology ... and service fulfillment continues to drive Nitto Avecia ... throughput capacities. , In Fall 2014, ... process equipment at its Milford, MA facility, which ...
Breaking Biology Technology:Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2
... Pearl Therapeutics, Inc.,a biopharmaceutical company developing treatments ... Colin Reisner, MD, FCCP,FAAAAI to the position of ... Development and Medical Affairs, and Michael Golden,to the ... "We are delighted to welcome Colin and ...
... New Clinical Trial Sites Recently Initiated To Support Ongoing ... Trials-, ... Including Four Phase II Trials in Major Disease Indications-, -Revenues Plus Cash On-Hand ... Advance ...
... HONG KONG, Dec. 20 /Xinhua-PRNewswire-FirstCall/ -- China Technology,Development ... a,provider of clean and renewable energy products and ... announced that it has completed,another step in its ... resources on the principal business of solar energy., ...
Cached Biology Technology:Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs 2Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs 3Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 2Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 3Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 4Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 5CTDC Announces the Disposal of Non-core Business 2
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. today ... (FIDO ® ) Alliance tm , an industry ... members commit to share technology and collaborate to ... are interoperable, more secure and private, and easier ... identity verification that protects sensitive user information and ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... time in a restful state akin to hibernation rather than ... in cells, new research suggests. And instead of being ... restful period appears to be a programmed step for RNA ... cell division and decide where proteins will work in a ...
... Leuven scientists (VIB/KU Leuven) are using zebrafish as a model ... the mechanism of amyotrophic lateral sclerosis (ALS). As a result, ... for a future ALS treatment. ALS is a progressive degenerative ... Their study has been published in the prestigious journal ...
... have long been appreciated, but now scientists at Duke ... makes mother,s milk better than infant formula in protecting ... in the August issue of the journal Current ... but not infant formula, fosters colonies of microbiotic flora ...
Cached Biology News:To cap or not to cap: Scientists find new RNA phenomenon that challenges dogma 2To cap or not to cap: Scientists find new RNA phenomenon that challenges dogma 3To cap or not to cap: Scientists find new RNA phenomenon that challenges dogma 4Zebra fish point the way towards new therapies for amyotrophic lateral sclerosis 2Breast milk promotes a different gut flora growth than infant formulas 2Breast milk promotes a different gut flora growth than infant formulas 3
...
...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...
Biology Products: